GNI Group Ltd Company Review & Valuation 2160

About GNI Group Ltd

GNI Group Ltd. researches, develops, manufactures, and sells pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. The company provides Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary for the treatment of radiation pneumonitis, which is in pilot study for Phase III clinical trials; Tamibarotene, a product for treating acute promyelocytic leukemia; and F351 that is in Phase II clinical trial for the treatment of liver fibrosis. In addition, the company is developing Etuary for the treatment of diabetic nephropathy and connective tissue disease associated interstitial lung disease; and F573 for acute liver failure and acute-on-chronic liver failure. Further, it is developing diabetic nephropathy; and connective tissue disease associated interstitial lung disease, which are in investigational new drug application stage. GNI Group Ltd. was founded in 2001 and is headquartered in Tokyo, Japan.

  • Tokyo, Japan
Primary Stock Exchange Listings

Ticker Symbol:

2160

Tokyo Stock Exchange
Japan

Stock Price

Performance

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Health Check

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Financial Reports

Registration required

Please login or create a free account to view all available contents of this section.

Create Account

Similar Companies

↑ back to top